Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Account Payables (2023 - 2025)

Contineum Therapeutics has reported Change in Account Payables over the past 3 years, most recently at $162000.0 for Q4 2025.

  • Quarterly results put Change in Account Payables at $162000.0 for Q4 2025, down 57.14% from a year ago — trailing twelve months through Dec 2025 was -$869000.0 (down 176.16% YoY), and the annual figure for FY2025 was -$869000.0, down 176.16%.
  • Change in Account Payables for Q4 2025 was $162000.0 at Contineum Therapeutics, up from -$1.2 million in the prior quarter.
  • Over the last five years, Change in Account Payables for CTNM hit a ceiling of $1.8 million in Q1 2025 and a floor of -$1.6 million in Q2 2025.
  • Median Change in Account Payables over the past 3 years was $166000.0 (2024), compared with a mean of $22666.7.
  • Peak annual rise in Change in Account Payables hit 2720.0% in 2025, while the deepest fall reached 1067.06% in 2025.
  • Contineum Therapeutics' Change in Account Payables stood at -$625000.0 in 2023, then surged by 160.48% to $378000.0 in 2024, then plummeted by 57.14% to $162000.0 in 2025.
  • The last three reported values for Change in Account Payables were $162000.0 (Q4 2025), -$1.2 million (Q3 2025), and -$1.6 million (Q2 2025) per Business Quant data.